|
Myocardial Infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
With relevance to atherogenesis, we found that patients with coronary artery disease (n=80) had raised plasma levels of APRIL as compared with controls (n=20), and APRIL immunoreactivity was detected in aggregated platelets within the ruptured plaque in patients with myocardial infarction and within macrophages in symptomatic carotid plaques.
|
19806256 |
2009 |
|
Coronary Arteriosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
With relevance to atherogenesis, we found that patients with coronary artery disease (n=80) had raised plasma levels of APRIL as compared with controls (n=20), and APRIL immunoreactivity was detected in aggregated platelets within the ruptured plaque in patients with myocardial infarction and within macrophages in symptomatic carotid plaques.
|
19806256 |
2009 |
|
Coronary heart disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
With relevance to atherogenesis, we found that patients with coronary artery disease (n=80) had raised plasma levels of APRIL as compared with controls (n=20), and APRIL immunoreactivity was detected in aggregated platelets within the ruptured plaque in patients with myocardial infarction and within macrophages in symptomatic carotid plaques.
|
19806256 |
2009 |
|
Coronary Artery Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
With relevance to atherogenesis, we found that patients with coronary artery disease (n=80) had raised plasma levels of APRIL as compared with controls (n=20), and APRIL immunoreactivity was detected in aggregated platelets within the ruptured plaque in patients with myocardial infarction and within macrophages in symptomatic carotid plaques.
|
19806256 |
2009 |
|
Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site
|
0.010 |
Biomarker
|
disease |
BEFREE |
Wild-type (WT) and APRIL Tg mice were infected with Helicobacter felis and Helicobacter pylori and compared with noninfected animals.
|
28460208 |
2017 |
|
Common Variable Immunodeficiency
|
0.040 |
Biomarker
|
disease |
BEFREE |
Whilst statistical analysis of ELISA results showed significant differences between patients and healthy controls, in our set of patients functional tests yielded no evidence for an involvement of autoantibodies against BAFF, APRIL, or IL-21 in the pathogenesis of CVID or sIgAD.
|
28651547 |
2017 |
|
Leukemogenesis
|
0.020 |
Biomarker
|
disease |
BEFREE |
We believe that APRIL Tg mice infected by Helicobacter species may represent a novel animal model of gastric lymphomagenesis.
|
28460208 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We previously reported the association of APRIL haplotypes formed by two nonsynonymous polymorphisms, Gly67Arg and Asn96Ser, with systemic lupus erythematosus.
|
21984075 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
We further analysed the prognostic value of BAFF and APRIL receptors expression in patients with CLL.
|
24245956 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We detected significantly increased APRIL levels in sera of B cell chronic lymphoid leukemia (B-CLL) patients, indicating that APRIL promotes onset of B-1-associated neoplasms and that APRIL antagonism may provide a therapeutic strategy to treat B-CLL patients.
|
15488762 |
2004 |
|
Chronic Lymphocytic Leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
We detected significantly increased APRIL levels in sera of B cell chronic lymphoid leukemia (B-CLL) patients, indicating that APRIL promotes onset of B-1-associated neoplasms and that APRIL antagonism may provide a therapeutic strategy to treat B-CLL patients.
|
15488762 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We also found overexpression of at least one proteoglycan with heparan sulfate chains (HS), which are coreceptors for APRIL and TACI, in tumors where APRIL is either overexpressed or is a prognostic factor.
|
19291294 |
2009 |
|
Influenza
|
0.030 |
Biomarker
|
disease |
BEFREE |
Using a CRISPR approach, we show that the human <u>a</u>cidic <u>n</u>uclear <u>p</u>hosphoproteins (ANPs) ANP32A and ANP32B are functionally redundant but essential host factors for mammalian-adapted influenza A virus (IAV) and influenza B virus (IBV) replication in human cells.
|
31217244 |
2019 |
|
Influenza A
|
0.020 |
Biomarker
|
disease |
BEFREE |
Using a CRISPR approach, we show that the human <u>a</u>cidic <u>n</u>uclear <u>p</u>hosphoproteins (ANPs) ANP32A and ANP32B are functionally redundant but essential host factors for mammalian-adapted influenza A virus (IAV) and influenza B virus (IBV) replication in human cells.
|
31217244 |
2019 |
|
Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Unlike TACI-Fc, BAFF-Trap bound BAFF but not APRIL (a proliferation-inducing ligand), and significantly suppressed the development of collagen-induced arthritis and adjuvant-induced arthritis.
|
31231554 |
2019 |
|
Asthma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Unlike other inflammatory diseases including autoimmune diseases and asthma, the circulating levels of BAFF, APRIL and TWEAK were not elevated in AE or SE patients compared with HCs and did not correlate with the disease severity or systemic IgE levels in AE patients.
|
21765951 |
2011 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two Gln187 mutants of human soluble APRIL inhibit proliferation of lung carcinoma A549 cells.
|
19997650 |
2009 |
|
Lupus Nephritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
To localize the respective proteins in the kidney, APRIL, BLyS, and BAFF-R were studied by immunohistochemistry in renal biopsies with proliferative (n=21) or membranous (n=8) lupus nephritis.
|
20890272 |
2011 |
|
Meningitis, Cryptococcal
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To investigate the levels of APRIL, BlyS and receptors as TACI, BCMA and BAFF-R in peripheral blood mononuclear cells (PBMC) of cryptococcal meningitis (CM) patients and its clinical significance.
|
19909733 |
2010 |
|
Common Variable Immunodeficiency
|
0.040 |
Biomarker
|
disease |
BEFREE |
This review delineates the contribution of interleukin (IL)-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-21, interferons, tumor necrosis factor (TNF)-α, IL-17, APRIL (a proliferation inducing ligand) and BAFF (B cell activating factor) in CVID disease and outline their potential therapeutic implications in these patients.
|
24827633 |
2014 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
These include the BAFF/APRIL dual inhibitor, atacicept, and the BAFF inhibitor, belimumab, which is approved as an add-on therapy for patients with active SLE.
|
28215100 |
2017 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
These findings suggest that BME has possible therapeutic potential in hepatoma cancer patients and that depletion of cellular APRIL is an important mechanism in the growth-inhibitory effect of BME.
|
18460811 |
2008 |
|
Liver neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
These findings suggest that BME has possible therapeutic potential in hepatoma cancer patients and that depletion of cellular APRIL is an important mechanism in the growth-inhibitory effect of BME.
|
18460811 |
2008 |
|
Autoimmune Diseases
|
0.060 |
Biomarker
|
group |
BEFREE |
These findings raise the possibility that active BLyS/APRIL heterotrimers may play a role in rheumatic and other autoimmune diseases and that other members of the TNF ligand superfamily may also form active soluble heterotrimers.
|
12370363 |
2002 |
|
Chronic Lymphocytic Leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
These findings indicate that APRIL has an important role in CLL and that the APRIL-TACI interaction might be a selective novel therapeutic target for human CLL.
|
24100449 |
2013 |